Rozalyn Levine Rodwin, MD, MHS
Assistant Professor in PediatricsCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Pediatric HEROS Survivorship Program
Small Group Leader, Scientific Inquiry Course
Contact Info
Pediatric Hematology & Oncology
333 Cedar St., LMP 2073
New Haven, Connecticut 06515
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Pediatric HEROS Survivorship Program
Small Group Leader, Scientific Inquiry Course
Contact Info
Pediatric Hematology & Oncology
333 Cedar St., LMP 2073
New Haven, Connecticut 06515
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Pediatric HEROS Survivorship Program
Small Group Leader, Scientific Inquiry Course
Contact Info
Pediatric Hematology & Oncology
333 Cedar St., LMP 2073
New Haven, Connecticut 06515
United States
About
Copy Link
Titles
Assistant Professor in Pediatrics
Director, Pediatric HEROS Survivorship Program; Small Group Leader, Scientific Inquiry Course
Biography
Dr. Rodwin completed her clinical fellowship in pediatric hematology/oncology at Yale in 2020, and subsequently conducted research in childhood cancer survivorship as a Pediatric Scholar and post-doctoral fellow in the Cancer Prevention and Control T32 Program. She has also served as director of the HEROS Childhood Cancer Survivorship Clinic since 2021. She looks forward to continuing her research aimed at minimizing treatment-related toxicities in childhood cancer survivors and leading the HEROS survivorship program.
Appointments
Pediatric Hematology & Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Cancer Prevention and Control
- Health Services & Implementation
- Janeway Society
- Pediatric Hematology & Oncology
- Pediatric Hematology & Oncology Program
- Pediatric HEROS Survivorship Program
- Pediatrics
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Assistant Professor
- Yale School of Medicine (2024)
- Instructor
- Yale School of Meidcine (2024)
- Post-Doctoral Fellow
- Yale School of Medicine (2021)
- Fellow
- Yale-New Haven Hospital (2020)
- MHS
- Yale School of Medicine
- Resident
- Yale-New Haven Hospital (2017)
- Intern
- Yale-New Haven Hospital (2015)
- MD
- New York Medical College (2014)
- BS
- Brandeis University
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-5243-3284
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Lyn Balsamo, PhD
Xiaomei Ma, PhD
Claudia Auerbach, APRN
Rong Wang, PhD
Beth L. Emerson, MD, MBA
Lajos Pusztai, MD, DPhil
Survivorship
Publications
2026
Diminished Quality of Life Despite Reduced Treatment in Children With B‐Lymphoblastic Leukemia: Children's Oncology Group AALL0932
Balsamo L, Kairalla J, Hibbitts E, Rodwin R, Devidas M, Dreyzin A, Winick N, Carroll W, Hunger S, Raetz E, Schore R, Loh M, Ness K, Angiolillo A, Kadan‐Lottick N. Diminished Quality of Life Despite Reduced Treatment in Children With B‐Lymphoblastic Leukemia: Children's Oncology Group AALL0932. Pediatric Blood & Cancer 2026, 73: e70029. PMID: 41486974, DOI: 10.1002/1545-5017.70029.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsQuality of lifePediatric QualityEmotional quality of lifeRandomized participantsDiminished qualityDiminished quality of lifeSchool-based servicesPhysical/occupational therapyServices SurveyBehavior Assessment Scale for Children-2Behavioral healthB-lymphoblastic leukemiaChildren-2Emotional functioningBaseline impairmentParent reportALL therapyB-ALLAssociated with impairmentLongitudinal modelSchool servicesTherapyParticipantsImpairmentTherapy end
2025
An Interactive, Structured Telephone Handoff Between a Survivorship Nurse Coordinator and Community Primary Care Provider (PCP) Clinics Is a Feasible and Acceptable Way to Improve Communication About Shared Patients’ Survivorship Care Needs
Kujawski S, Ross W, Santiago‐Rivera Y, Rotatori J, Balsamo L, Gardner J, Auerbach C, Kadan‐Lottick N, Rodwin R. An Interactive, Structured Telephone Handoff Between a Survivorship Nurse Coordinator and Community Primary Care Provider (PCP) Clinics Is a Feasible and Acceptable Way to Improve Communication About Shared Patients’ Survivorship Care Needs. Pediatric Blood & Cancer 2025, 73: e70062. PMID: 41454785, DOI: 10.1002/1545-5017.70062.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPrimary care providersPrimary care provider clinicsSurvivorship care needsNurse coordinatorSurvivorship careCare needsCare providersCommunity primary care providersChildhood cancer survivorsSurvivorship clinicCancer survivorsYears post-treatmentNursesCareSurvivorshipProvidersClinicAcceptable wayNeedsHandoffTelephonePost-treatmentSurvivorsAcceptanceCommunityCaregivers’ Perspectives on Changes in Family Life During B‐ALL Therapy: A Qualitative Study From the Children's Oncology Group
Dreyzin A, Ware M, Stumbras K, Kairalla J, Hibbitts E, Mossman B, Balsamo L, Rodwin R, Ness K, Conley C, Raetz E, Devidas M, Sung L, Loh M, Hunger S, Schore R, Angiolillo A, Kadan‐Lottick N. Caregivers’ Perspectives on Changes in Family Life During B‐ALL Therapy: A Qualitative Study From the Children's Oncology Group. Pediatric Blood & Cancer 2025, 72: e32057-e32057. PMID: 40974099, PMCID: PMC12700121, DOI: 10.1002/pbc.32057.Peer-Reviewed Original ResearchAltmetricConceptsCaregiver perspectivesChild's diagnosisPositive changesCaregivers of childrenFamily-centered careInductive content analysisMonths post-diagnosisCare needsFamily lifePost-diagnosisCaregiversFamily supportQualitative studyDescriptive statisticsPatient healthPositive family changeNegative changesCommunity supportChildren's Oncology GroupB-acute lymphoblastic leukemiaFamily membersContent analysisDaily routineCareAncillary studies
2024
Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic
Kang L, Kadan-Lottick N, Rotatori J, Kujawski S, Messerschmidt E, Auerbach C, Balsamo L, Lustberg M, Ma X, Rodwin R. Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic. Seminars In Oncology Nursing 2024, 40: 151716. PMID: 39164160, DOI: 10.1016/j.soncn.2024.151716.Peer-Reviewed Original ResearchCitationsAltmetricConceptsChildhood cancer survivorsChemotherapy-induced peripheral neuropathyCharacteristics of survivorsPhysical therapyPercentage of adultsPT referralSurvivorship clinicCancer survivorsAttended PTPT attendanceNeighborhood characteristicsChemotherapy-induced peripheral neuropathy symptomsCancer survivorship clinicPhysical therapy referralsHigh school diplomaSurvivor educationCare coordinationOlder survivorsTherapy referralsImprove attendanceMedian percentageCancer diagnosisSchool diplomaPercentage of householdsAttendanceMotor and sensory impairment in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime Cohort (SJLIFE)
Rodwin R, Wang F, Lu L, Li Z, Srivastava D, Phillips N, Khan R, Brinkman T, Krull K, Boop F, Armstrong G, Merchant T, Gajjar A, Robison L, Hudson M, Kadan‐Lottick N, Ness K. Motor and sensory impairment in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime Cohort (SJLIFE). Cancer Medicine 2024, 13: e7422. PMID: 39056576, PMCID: PMC11273544, DOI: 10.1002/cam4.7422.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSt. Jude Lifetime CohortQuality of lifeChildhood central nervous systemSurvivors of childhood CNS tumorsSensory impairmentChildhood CNS tumorsImpaired physical quality of lifeCentral nervous systemPhysical quality of lifeMotor impairmentCNS tumorsCommon Terminology Criteria for Adverse EventsModified total neuropathy scoreMultivariate modelIn-person evaluationAssociated with older ageClinical assessmentTotal Neuropathy ScoreNervous systemExposure to etoposideModified Common Terminology Criteria for Adverse EventsPrevalence of motorTreating motor impairmentIn-personCraniospinal irradiation
2023
Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia
Rodwin R, DelRocco N, Hibbitts E, Devidas M, Whitley M, Mohrmann C, Schore R, Raetz E, Winick N, Hunger S, Loh M, Hockenberry M, Ma X, Angiolillo A, Ness K, Kairalla J, Kadan‐Lottick N. Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer 2023, 70: e30634. PMID: 37592363, PMCID: PMC10552080, DOI: 10.1002/pbc.30634.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyLymphoblastic leukemiaPediatric Outcomes Data Collection InstrumentPT/OTSensory peripheral neuropathyAcute lymphoblastic leukemiaPredictor of motorProxy-report measuresCommon conditionOccupational therapistsNeuropathyChildrenLeukemiaFunction studiesResponse
2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkersHispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study
Graham C, Metayer C, Morimoto LM, Wiemels JL, Siddique A, Di M, Rodwin RL, Kadan-Lottick NS, Ma X, Wang R. Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 1788-1795. PMID: 35709749, PMCID: PMC9444874, DOI: 10.1158/1055-9965.epi-22-0335.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNon-Hispanic whitesHodgkin's lymphomaCase-control studyBirth characteristicsMaternal birthplaceMaternal agePopulation-based case-control studyMultivariable logistic regression modelConfidence intervalsEthnic differencesEarly-onset cancersPotential ethnic differencesForeign-born mothersLogistic regression modelsEthnicity differencesRace/ethnicityYear of birthLymphomaPaternal ageFemale HispanicsHispanic casesMale HispanicsHodgkinAgeRiskPersistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia
Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. Journal Of The National Cancer Institute 2022, 114: 1167-1175. PMID: 35552709, PMCID: PMC9360458, DOI: 10.1093/jnci/djac095.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsPhysical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia
Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice 2022, 18: e1060-e1068. PMID: 35427182, PMCID: PMC9287366, DOI: 10.1200/op.21.00796.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute lymphoblastic leukemiaPediatric acute lymphoblastic leukemiaPhysical therapyPhysical functionLymphoblastic leukemiaNeuromuscular conditionsImpaired physical functionPhysical therapy utilizationPremier Healthcare DatabasePediatric hematologists/oncologistsEarly physical therapyInpatient physical therapyHematologists/oncologistsLong-term healthCohort studyFirst hospitalizationMultivariable analysisTherapy utilizationClinical variablesTeaching hospitalHealthcare databasesPatientsAddress disparitiesHospitalAge 10
Clinical Trials
Current Trials
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
IRB ID1512016865RoleSub InvestigatorPrimary Completion Date01/31/2100Recruiting ParticipantsA Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
IRB ID2000028880RoleSub InvestigatorPrimary Completion Date09/30/2027Recruiting ParticipantsDetection of Chemotherapy Induced Peripheral Neuropathy
IRB ID2000028597RolePrincipal InvestigatorPrimary Completion Date03/31/2022Recruiting ParticipantsA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
IRB ID2000026862RoleSub InvestigatorPrimary Completion Date06/30/2029Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Activities
activity Children's Oncology Group
2017 - PresentProfessional OrganizationsMemberactivity Caregivers’ perspective on family life during treatment for B-ALL from the Children’s Oncology Group.
05/10/2023 - PresentOral PresentationThe American Society of Pediatric Hematology OncologyDetailsFort Worth, TX, United StatesCollaborators- Dreyzin A
- Stumbras K
- Kairalla JA
- Hibbitts E
- Lyn Balsamo, PhD
- Rozalyn Levine Rodwin, MD, MHS
- Raetz E
- Devidas M
- Loh M
- Schore R
- Angiolillo A
- Kadan-Lottick NS
Honors
honor American Society of Clinical Oncology Conquer Cancer Merit Award
05/01/2020National Award
Teaching & Mentoring
Copy Link
Teaching
Didactic Hematology/Oncology Fellow Lecture Series
Clinical Faculty MemberLecture SettingDetails7/1/2020 - PresentForHouse Staff1 Average Instructional Hours Per YearDidactic MD 1250: Scientific Inquiry
Clinical Faculty MemberLecture SettingDetails9/1/2023 - PresentForGraduate7 Average Instructional Hours Per YearThis portion of the first-year curriculum is one of several coordinated and complementary curricular offerings designed to prepare Yale School of Medicine (YSM) students for careers in the rigorous consideration, execution, and application of research which results in the betterment of human health and wellbeing.
The YSM research requirement ensures that students learn and master research skills, such identifying knowledge gaps, formulating research questions, designing rigorous and reproducible investigative approaches using the highest standards of methodological rigor, analyzing data, summarizing results, and presenting one’s work to communities of interest including patients. An important feature of the research curriculum is the formal instruction students receive in the first year which is designed to successfully launch them on the path of acquiring and practicing these essential skills on their own.
The goal of the Scientific Inquiry curriculum is to initiate students on their four- to five-year journey of learning, observing, and practicing the skills required to conduct research related to health and medicine. Specifically, first-year students will receive instruction regarding the YSM thesis requirement as well as the preparation and support needed to develop methodologically rigorous research projects. Although the course is framed around the mentored research that many students will conduct during the summer between the first and second years of medical school, the same principles taught in the course will also apply to research conducted during the Advanced Training Period, in support of the MD thesis requirement, and beyond.
The curriculum is led by physician-scientists and clinician-investigators with successful research programs who also serve as role models and mentors to students as they begin to assume their professional identities. The first year involves seven sessions dedicated to the formal support of research project development, mentor selection, identification of knowledge gaps via literature review, and the creation of a written research proposal. It is expected that students will develop impactful research projects that are methodologically rigorous, significant, and innovative. The curriculum culminates in the required submission of a research proposal, completion of which serves as the course assessment. The proposal must contain the following components: background/scientific premise; the research question(s) being asked with hypotheses being tested (not relevant for qualitative research or history of medicine research); specific aims; methods, including a proposed statistical analysis plan; challenges and limitations; statement of scientific impact and relevance for communities of interest including patients. All MD students are required to submit a completed research proposal in order to successfully receive credit for this course.
Didactic Pediatric Senior Resident Academic Half Day
LecturerLecture SettingDetails11/1/2020 - PresentForHouse Staff1 Average Instructional Hours Per YearSessions of three one-hour lectures on specialty/themed topics encompassing the breadth of pediatrics.
Mentoring
Madhumitha Saravanan
Medical student2025 - PresentJingyi Zhang
Graduate student2025 - PresentMadalyn Gibson-Williams
Graduate student2025 - PresentLeah Hirschman
Fellow2024 - Present
Clinical Care
Copy Link
Overview
Rozalyn Levine Rodwin, MD, specializes in pediatric hematology and oncology, with a focus on childhood cancer survivorship. She is dedicated to improving the long-term health outcomes of children who have overcome cancer, addressing the chronic conditions that can arise from cancer treatments.
"Most childhood cancer patients will be cured of their cancer,” Dr. Rodwin says. “However, even after they're cured, survivors are at risk for a host of chronic conditions from the treatment they received, which can affect them for the rest of their lives."
As the director of the HEROS Childhood Cancer Survivorship Clinic at Smilow Cancer Hospital, Dr. Rodwin leads efforts to provide specialized care for survivors, ensuring they receive the necessary follow-up and support. "My patients and their families inspire me to work as a pediatric oncologist,” she says. “It is a privilege to be part of their care, and to help them navigate their diagnosis.”
Also an assistant professor at Yale School of Medicine, Dr. Rodwin’s research aims to minimize treatment-related toxicities in childhood cancer survivors. She completed her medical degree at New York Medical College, followed by a clinical fellowship in pediatric hematology/oncology at Yale School of Medicine.
Clinical Specialties
Fact Sheets
Acute Lymphoblastic Leukemia (ALL)
Learn More on Yale MedicineNeutropenia
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale MedicineThrombocytopenia
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- February 03, 2026
The Tommy Fund: A Legacy of Support and Growth for Pediatric Oncology
- September 10, 2025
Hyundai Hope on Wheels Funds Childhood Cancer Research and Patient Care at Yale
- October 14, 2024
Preserving Hope: Fertility Care for Patients with Cancer and Hematological Disorders
- October 09, 2024
Hyundai Hope on Wheels Grant Provides $100K for Childhood Cancer Research at Yale
Get In Touch
Copy Link
Contacts
Pediatric Hematology & Oncology
333 Cedar St., LMP 2073
New Haven, Connecticut 06515
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.